Suppr超能文献

乳糜泻与甲状腺功能减退症。

Celiac disease and hypothyroidism.

机构信息

Department of Medicine, University of Vermont/Fletcher Allen Health Care, Burlington, USA.

出版信息

Am J Med. 2012 Mar;125(3):278-82. doi: 10.1016/j.amjmed.2011.09.003.

Abstract

BACKGROUND

Celiac disease is more common in patients with hypothyroidism. Malabsorption of levothyroxine has not been studied in this population. We sought to determine if levothyroxine dosing was influenced by the presence and treatment of celiac disease.

METHODS

This retrospective study was conducted at an academic medical center. Cases had hypothyroidism and celiac disease. Controls had hypothyroidism alone and were selected randomly through the endocrinology clinic records. Celiac disease was defined as representative pathology with positive serology. Age, sex, height, weight, body mass index, creatinine, and medical comorbidity were assessed for cases and controls. The levothyroxine dose and weight-based levothyroxine dose necessary to maintain a euthyroid state was evaluated for controls, and before and after celiac disease therapy for cases.

RESULTS

Celiac disease was identified in 152 patients, and 22 patients had concomitant hypothyroidism (14.5%). Seven cases met inclusion criteria. Overall, 200 control patients were identified. The mean celiac disease pretreatment levothyroxine dose and weight-based levothyroxine dose needed to maintain a euthyroid state were higher in cases than in controls (154 μg vs 106 μg, P=.007, and 2.6 μg/kg vs 1.3 μg/kg, P <.001). Doses decreased significantly after treatment of celiac disease (154 μg vs 111 μg, P=.03; and 2.64 μg/kg vs 1.89 μg/kg, P=.04). All cases required at least 125 μg of levothyroxine initially to maintain a euthyroid state.

CONCLUSIONS

Levothyroxine malabsorption likely occurs with hypothyroidism and untreated celiac disease. Absorption may improve after celiac disease treatment. Screening for celiac disease in patients with hypothyroidism requiring elevated levothyroxine doses warrants further investigation.

摘要

背景

甲状腺功能减退症患者中更常见乳糜泻。尚未研究该人群中左甲状腺素的吸收不良。我们旨在确定乳糜泻的存在和治疗是否会影响左甲状腺素的剂量。

方法

本回顾性研究在学术医疗中心进行。病例为甲状腺功能减退症伴乳糜泻,对照组为单纯甲状腺功能减退症,通过内分泌科门诊记录随机选择。乳糜泻的定义为有代表性的病理学和阳性血清学。评估病例和对照组的年龄、性别、身高、体重、体重指数、肌酐和合并症。评估对照组的左甲状腺素剂量和维持甲状腺功能正常所需的左甲状腺素剂量,并评估病例在乳糜泻治疗前后的左甲状腺素剂量。

结果

发现 152 例乳糜泻患者,其中 22 例同时患有甲状腺功能减退症(14.5%)。7 例符合纳入标准。共确定 200 例对照组患者。与对照组相比,乳糜泻治疗前的病例左甲状腺素剂量和维持甲状腺功能正常所需的左甲状腺素剂量更高(154μg vs 106μg,P=0.007,2.6μg/kg vs 1.3μg/kg,P<0.001)。乳糜泻治疗后剂量显著降低(154μg vs 111μg,P=0.03;2.64μg/kg vs 1.89μg/kg,P=0.04)。所有病例最初至少需要 125μg 的左甲状腺素才能维持甲状腺功能正常。

结论

甲状腺功能减退症和未经治疗的乳糜泻可能导致左甲状腺素吸收不良。乳糜泻治疗后吸收可能改善。对需要升高左甲状腺素剂量的甲状腺功能减退症患者进行乳糜泻筛查值得进一步研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验